RepliCel activity while in Japan includes co-presenting hair regeneration
technology with partner, Shiseido, at the Congress of the Japanese
Society for Regenerative Medicine
VANCOUVER, March 12,
2015 /CNW/ - RepliCel Life Sciences Inc. (TSX.V: RP)
(OTCQB: REPCF), a clinical stage regenerative medicine company
focused on the development of autologous cell therapies announced
today that it will be presenting at two biotech conferences in
Japan in March.
Additionally, representatives of RepliCel's management and R&D
teams will be in Japan for over a
week conducting closed-door meetings with its partner Shiseido and
the Japanese Pharmaceutical and Medical Devices Agency (PMDA), as
well as numerous meetings scheduled with potential investors and
strategic partners with the support of the Tokyo-based office of Euro Pacific Canada
which is supporting RepliCel's partnering activity in Japan.
On March
20th at 12:00 noon local time, RepliCel's Chief
Medical Officer, Dr. Rolf Hoffmann
and licensing partner Shiseido Company Ltd.'s, Dr.'s Manabu Ohyama and Jiro
Kishimoto, will be presenting at the 14th
Congress of the Japanese Society for Regenerative Medicine (JSRM)
2015 in Yokohama, Japan.
Leading the discussion will be Dr. Manabu Ohyama who will talk on the "Use of human
induced pluripotent stem cells for the generation of hair inductive
dermal cells." Dr. Hoffmann will then present on the "Background
and use of dermal sheath cup cells in cell-based therapy for
Androgenetic Alopecia." Closing the group will be Dr. Jiro Kishimoto, with a talk entitled, "Our
approach for a hair regeneration clinical research study under
Japan's new 'regenerative
medicine' law." This congress is being held Thursday March 19th to Saturday March 21st 2015, at the
PACIFICO Yokohama 1-1-1, Minato Mirai, Nishi-ku.
"We are very pleased to have been invited to
speak at the JSRM, especially given the leadership role
Japan's scientific community is
playing in the development of the science underlying regenerative
medicines," commented Dr. Rolf
Hoffmann. "We strongly believe that the current and
growing activity in cell therapy will bring dramatic changes in how
diseases are treated."
On March 24 at
2:30 PM local time, RepliCel's CEO,
David Hall, will be presenting at
the 12th Annual BioAsia International Conference in
Tokyo, Japan. Mr. Hall will
present RepliCel's platform technologies including clinical
activities as well as the company's unique position as one of the
few foreign regenerative medicine companies with an active Japanese
partnership poised to commence clinical trials in Japan.
"We are huge supporters of Japan's initiatives and leadership in
regenerative medicine," stated RepliCel CEO, David Hall. "Our company is proud of our
license with Shiseido and is moving forward with additional
licensing and partnership discussions with Japanese partners around
our other clinical programs in chronic tendinosis and
dermatological applications. We are impressed that the Japanese
policy reforms have already generated measurable enthusiasm among
both Japanese investors and therapeutic companies for being part of
bringing foreign cell therapy technologies, like RepliCel's, to
Japan."
About RepliCel
RepliCel is a
regenerative medicine company focused on developing autologous cell
therapies that address diseases caused by a deficit of healthy
cells required for normal healing and function. The company's
RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat
chronic tendinosis, UV-damaged or aged skin, and pattern baldness.
Shiseido has an exclusive license for RCH-01 in certain Asian
countries including Japan,
China and South Korea. All product candidates are based
on RepliCel's innovative technology utilizing cell populations
isolated from a patient's own healthy hair follicles. The company
is also developing a propriety injection device optimized for the
administration of its products and licensable for use with other
dermatology applications. The Company's product pipeline is
comprised of multiple clinical trials anticipated to launch through
2015 in addition to Shiseido's own clinical trial of RCH-01 and the
device in late prototype development. To learn more about RepliCel,
please visit our company website at www.replicel.com.
This press release contains forward-looking
information. There are numerous risks and uncertainties that could
cause actual results and RepliCel's plans and objectives to differ
materially from those expressed in the forward-looking information,
including: approval to conduct clinical trials; negative results
from the Company's clinical trials; the effects of government
regulation on the Company's business; risks associated with the
Company's ability to obtain and protect rights to its intellectual
property; risks and uncertainties associated with the Company's
ability to raise additional capital; and other factors beyond the
Company's control. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, RepliCel does not intend to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE RepliCel Life Sciences Inc.